The estimated Net Worth of Albert Vaccinex (Rochester)... is at least $27.2 million dollars as of 14 March 2019. Albert Rochester owns over 2,000 units of Vaccinex Inc stock worth over $27,161,959 and over the last 6 years Albert sold VCNX stock worth over $0.
Sign up
Albert Rochester VCNX stock SEC Form 4 insiders trading
Albert has made over 2 trades of the Vaccinex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Albert bought 2,000 units of VCNX stock worth $7,960 on 14 March 2019.
The largest trade Albert's ever made was buying 2,000 units of Vaccinex Inc stock on 14 March 2019 worth over $7,960. On average, Albert trades about 2,000 units every 0 days since 2019. As of 14 March 2019 Albert still owns at least 4,790,469 units of Vaccinex Inc stock.
You can see the complete history of Albert Rochester stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Albert Rochester's mailing address?
Albert's mailing address filed with the SEC is 181 BAY STREET181 BAY STREET, SUITE 250SUITE 250, TORONTOTORONTO, A6A6, M5J 2T3M5J 2T3.
Insiders trading at Vaccinex Inc
Over the last 6 years, insiders at Vaccinex Inc have traded over $3,161 worth of Vaccinex Inc stock and bought 14,062,785 units worth $29,583,294 . The most active insiders traders include Albertfcmi Parent Co. Fried..., Maurice Zauderer et Maurice Vaccinex (Rochester.... On average, Vaccinex Inc executives and independent directors trade stock every 61 days with the average trade being worth of $2,417,268. The most recent stock trade was executed by Albertfcmi Parent Co. Fried... on 9 August 2024, trading 100 units of VCNX stock currently worth $451.
What does Vaccinex Inc do?
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
What does Vaccinex Inc's logo look like?
Complete history of Albert Rochester stock trades at Vaccinex Inc
Vaccinex Inc executives and stock owners
Vaccinex Inc executives and other stock owners filed with the SEC include:
-
Dr. Maurice Zauderer Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Ernest S. Smith Ph.D.,
Sr. VP of Research & Chief Scientific Officer -
Scott E. Royer C.F.A., M.B.A.,
Chief Financial Officer -
Dr. John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Elizabeth E. Evans Ph.D.,
COO and Sr. VP of Discovery & Translational Medicine -
Elizabeth E. Evans,
COO and Sr. VP of Discovery & Translational Medicine -
John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Deepak M. Sahasrabudhe,
Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor -
Maurice Vaccinex (Rochester...,
President and CEO -
Jill Sanchez,
Chief Financial Officer -
Albert Vaccinex (Rochester)...,
-
Bala S Manian,
Director -
Jeff Goater,
Director -
Albertfcmi Parent Co. Fried...,
-
Robert Scala,
Chief Commercial Officer -
Jacob B. Frieberg,
Director -
Raymond E. Watkins,
SVP & Chief Operating Officer -
Barbara Yanni,
Director -
Alejandro M. Berlin,
Director -
Inc. Vaccinex,,
Director -
Ernest S. Smith,
SVP, Research & CSO -
John E. Leonard,
SVP, Development -
Scott E. Royer,
Chief Financial Officer -
Strydonck, Gerald E. Van,
Director -
Elizabeth E. Evans,
Chief Operating Officer -
Maurice Zauderer,
President and CEO